Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 7—July 2020

Paradoxal Trends in Azole-Resistant Aspergillus fumigatus in a National Multicenter Surveillance Program, the Netherlands, 2013–2018

Pieter P.A. Lestrade, Jochem B. Buil, Martha T. van der Beek, Ed J. Kuijper, Karin van Dijk, Greetje A. Kampinga, Bart J.A. Rijnders, Alieke G. Vonk, Sabine C. de Greeff, Annelot F. Schoffelen, Jaap van Dissel, Jacques F. Meis, Willem J.G. Melchers, Paul E. VerweijComments to Author , and Kuijper
Author affiliations: VieCuri Hospital, Venlo, the Netherlands (P.P.A. Lestrade); Center of Expertise in Mycology Radboud University Medical Center/Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands (J.B. Buil, J.F. Meis, W.J.G. Melchers, P.E. Verweij); Leiden University Medical Center, Leiden, the Netherlands (M.T. van der Beek, E.J. Kuijper); Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands (K. van Dijk); University of Groningen, University Medical Center Groningen, Groningen, the Netherlands (G.A. Kampinga); Erasmus Medical Center, Rotterdam, the Netherlands (B.J.A. Rijnders, A.G. Vonk); Center for Infectious Disease Control, Dutch National Institute for Public Health and the Environment, Bilthoven, the Netherlands (S.C. de Greeff, A.F. Schoffelen, J. van Dissel)

Main Article

Table 2

Resistance profiles of 640 azole-resistant Aspergillus fumigatus isolates classified according to voriconazole clinical breakpoints in a national multicenter surveillance program in the Netherlands, 2013–2018*

Voriconazole classification (no. isolates) No. (%) isolates
Itraconazole Posaconazole Isavuconazole
Voriconazole-susceptible (18)
Susceptible 0 1 (5.6) 6/16 (37.5)
Intermediate 1 (5.6) 2 (11.1) NA
17 (94.4)
15 (83.3)
10/16 (62.5)
Voriconazole-intermediate (124)
Susceptible 0 4 (3.2) 2/121 (1.7)
Intermediate 6 (4.8) 19 (15.3) NA
118 (95.2)
101 (81.5)
119/121 (98.3)
Voriconazole-resistant (498)
Susceptible 50 (10) 8 (1.6) 0/396 (0)
Intermediate 25 (5) 28 (5.6) NA
Resistant 423 (85) 462 (92.8) 396/396 (100)

*Isavuconazole was not measured before 2014; therefore, denominator is different in comparison with itraconazole and posaconazole. NA, not applicable (no intermediate susceptibility category defined for isavuconazole).

Main Article

Page created: May 05, 2020
Page updated: June 18, 2020
Page reviewed: June 18, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.